• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Veradigm Inc.

    5/16/24 5:19:34 PM ET
    $MDRX
    EDP Services
    Technology
    Get the next $MDRX alert in real time by email
    SC 13D 1 n4288_x1-sc13d.htm SC 13D

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

    ______________

     

    SCHEDULE 13D

    (Rule 13d-101)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

    § 240.13d-2(a)

     

    (Amendment No. )1

     

    Veradigm Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.01 per share

    (Title of Class of Securities)

     

    01988P108

    (CUSIP Number)

     

    KENT LAKE CAPITAL LLC

    BENJAMIN NATTER

    300 East 2nd Street, Suite 1510, #1033

    Reno, Nevada 89501

     

    SEBASTIAN ALSHEIMER, ESQ.

    WILSON SONSINI GOODRICH & ROSATI

    1301 Avenue of the Americas

    New York, New York 10019

    (212) 999-5800

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    May 16, 2024

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. £.

     

     

    1       The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

       

     

           Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

    (Continued on following pages)

       

     

     

     

    1

    NAME OF REPORTING PERSONS

     

     

    Kent Lake Partners LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*(a) £

    (b) £

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    WC

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)£
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    DELAWARE

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7

    SOLE VOTING POWER

     

    - 0 -

    8

    SHARED VOTING POWER

     

    5,385,000

    9

    SOLE DISPOSITIVE POWER

     

    - 0 -

    10

    SHARED DISPOSITIVE POWER

     

    5,385,000

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,385,000

    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES£
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    5.00%

    14

    TYPE OF REPORTING PERSON

     

    PN

     

       

     

     

     

    1

    NAME OF REPORTING PERSONS

     

    Kent Lake Capital LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*(a) £

    (b) £

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)£
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    DELAWARE

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7

    SOLE VOTING POWER

     

    - 0 -

    8

    SHARED VOTING POWER

     

     

    5,385,000

    9

    SOLE DISPOSITIVE POWER

     

    - 0 -

    10

    SHARED DISPOSITIVE POWER

     

    5,385,000

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,385,000

    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES£
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    5.00%

    14

    TYPE OF REPORTING PERSON

     

    IA, HC

       

     

     

     


    1

    NAME OF REPORTING PERSONS

     

    Benjamin Natter

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*(a) £

    (b) £

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)£
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

     

    UNITED STATES OF AMERICA

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7

    SOLE VOTING POWER

     

    - 0 -

    8

    SHARED VOTING POWER

     

     

    5,385,000

    9

    SOLE DISPOSITIVE POWER

     

    - 0 -

    10

    SHARED DISPOSITIVE POWER

     

     

    5,385,000

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     

    5,385,000

    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES£
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    5.00%

    14

    TYPE OF REPORTING PERSON

     

    IN, HC

     

       

     

     

    The following constitutes the Schedule 13D filed by the undersigned (the “Schedule 13D”).

    Item 1. Security and Issuer.

    This statement relates to the Common Stock, par value $0.01 per share (the “Shares”), of Veradigm Inc., a Delaware corporation (the “Issuer”). The address of the principal executive offices of the Issuer is 222 Merchandise Mart, Chicago, Illinois 60654

    Item 2. Identity and Background.

    (a)       This statement is filed by the following (collectively, the “Reporting Persons”):

     

      (i) Kent Lake Partners LP, a Delaware limited partnership (“Kent Lake Partners”), with respect to the Shares directly and beneficially owned by it;

     

      (ii) Kent Lake Capital LLC, a Delaware limited liability company (“Kent Lake Capital”), as the general partner of Kent Lake Partners;

     

      (iii) Benjamin Natter, as the Managing Member of Kent Lake Capital;

      

    (b)       The principal business address of each of the Reporting Persons is 300 East 2nd Street, Suite 1510, #1033, Reno, Nevada 89501.

     

    (c)       The principal business of Kent Lake Partners is investing in securities. The principal business of Kent Lake Capital is serving as an investment adviser and as the general partner to Kent Lake Partners. The principal occupation of Mr. Natter is serving as the Managing Member of Kent Lake Capital.

     

    (d)       During the last five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    (e)       During the past five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which such entity or person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    (f)       Mr. Natter is a citizen of the United States.

     

      Item 3. Source and Amount of Funds or Other Consideration.

    The securities purchased by Kent Lake Partners, were purchased with working capital in open market purchases as set forth in Schedule A, which is incorporated by reference herein. The aggregate purchase price of the 5,385,000 Shares directly owned by Kent Lake Partners is approximately $41,945,020, including brokerage commissions.

    Item 4.Purpose of Transaction.

    The Reporting Persons purchased the Shares based on the Reporting Persons’ belief that the Shares, when purchased, were undervalued and represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting

       

     

    Persons, and the availability of Shares at prices that would make the purchase or sale of Shares desirable, the Reporting Persons may endeavor to increase or decrease their position in the Issuer through, among other things, the purchase or sale of Shares on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable.

    No Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein. The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer’s financial position and investment strategy, the price levels of the Shares, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate including, without limitation, engaging in communications with management and the Board of Directors of the Issuer, engaging in discussions with stockholders of the Issuer or other third parties about the Issuer and the Reporting Persons’ investment, including potential business combinations or dispositions involving the Issuer or certain of its businesses, making recommendations or proposals to the Issuer concerning changes to the capitalization, ownership structure, board structure (including board composition), potential business combinations or dispositions involving the Issuer or certain of its businesses, or suggestions for improving the Issuer’s financial and/or operational performance, purchasing additional Shares, selling some or all of their Shares, engaging in short selling of or any hedging or similar transaction with respect to the Shares, including swaps and other derivative instruments, or changing their intention with respect to any and all matters referred to in Item 4.

    Item 5.Interest in Securities of the Issuer.

     

    (a)As of the date hereof, the Reporting Persons beneficially own 5,385,000 shares in the aggregate, representing approximately 5% of the outstanding Shares. The aggregate percentage of Shares reported owned by the Reporting Persons herein is based upon approximately 107,639,978 outstanding, as of April 9, 2024, which is the total number of shares outstanding as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 10, 2024.

     

    (b)The Reporting Persons have sole voting power and sole investment power with respect to the Shares beneficially owned by the Reporting Persons.

     

    (c)During the past 60 days, none of the Reporting Persons has effected any transaction in the Shares, except as set forth on Schedule A.

     

    (d)No person other than the Reporting Persons is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the Share.

     

    (e)Not applicable.

     

    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

    On May 16, 2024, the Reporting Persons entered into a Joint Filing Agreement in which the Reporting Persons agreed to the joint filing on behalf of each of them of statements on Schedule 13D with respect to the securities of the Issuer to the extent required by applicable law.  The Joint Filing Agreement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

     

       

     

    Other than as described herein, there are no contracts, arrangements, understandings or relationships among the Reporting Persons, or between the Reporting Persons and any other person, with respect to the securities of the Issuer.

     

    Item 7.Material to be Filed as Exhibits.

    Item 7 is hereby amended to add the following exhibit:

    99.1Joint Filing Agreement, dated May 16, 2024.

     

     

       

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: May 16, 2024

     

    KENT LAKE PARTNERS LP

     

     

    By: Kent Lake GP LLC, its General Partner

     

      By: /s/ Benjamin Natter
        Name: Benjamin Natter
        Title: Managing Member

     

     

    KENT LAKE CAPITAL LLC

     

      By: /s/ Benjamin Natter
        Name: Benjamin Natter
        Title: Managing Member

     

     

      /s/ Benjamin Natter
      BENJAMIN NATTER

     

     

       

     

     

    SCHEDULE A

     

    Transactions in Shares effected by Kent Lake Partners During the Past Sixty Days

     

    Nature of Transaction Amount of Securities
    Purchased/(Sold)

     

    Price ($)

    Date of
    Purchase/Sale

     

    Sale of Common Stock (31,258) $8.5133 03/18/2024
    Sale of Common Stock (21,330) $8.5775 03/19/2024
    Sale of Common Stock (44,047) $8.2784 03/21/2024
    Sale of Common Stock (15,000) $8.0000 03/22/2024
    Sale of Common Stock (8,964) $8.0000 03/25/2024
    Sale of Common Stock (43,180) $8.0000 03/26/2024
    Sale of Common Stock (255,312) $7.9787 03/26/2024
    Sale of Common Stock (17,590) $7.9185 03/27/2024
    Sale of Common Stock (2,352) $8.0000 03/28/2024
    Sale of Common Stock (3,069) $8.0000 04/01/2024
    Sale of Common Stock (9,000) $8.0496 04/02/2024
    Sale of Common Stock (25,000) $8.0147 04/11/2024
    Purchase of Common Stock 10,000 $7.8500 05/16/2024

       

     

    Get the next $MDRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MDRX

    DatePrice TargetRatingAnalyst
    3/19/2024$15.00 → $10.00Buy → Hold
    Deutsche Bank
    1/3/2024$11.00Equal Weight
    Barclays
    7/6/2023Buy → Hold
    Argus
    4/12/2023$13.00Equal-Weight
    Stephens
    2/1/2023$17.00 → $18.50Overweight → Neutral
    Piper Sandler
    12/7/2022$26.00Hold → Buy
    Argus
    11/9/2022$22.00 → $23.00Neutral → Buy
    Goldman
    11/4/2022$17.00Overweight
    Piper Sandler
    More analyst ratings

    $MDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO Langan Thomas covered exercise/tax liability with 1,893 shares, decreasing direct ownership by 0.57% to 327,528 units (SEC Form 4)

      4 - Veradigm Inc. (0001124804) (Issuer)

      5/5/25 4:08:52 PM ET
      $MDRX
      EDP Services
      Technology
    • CEO Langan Thomas covered exercise/tax liability with 2,481 shares, decreasing direct ownership by 0.75% to 329,421 units (SEC Form 4)

      4 - Veradigm Inc. (0001124804) (Issuer)

      4/3/25 4:55:05 PM ET
      $MDRX
      EDP Services
      Technology
    • SVP & Chief HR Officer Hammond Lisa covered exercise/tax liability with 227 shares, decreasing direct ownership by 0.19% to 119,648 units (SEC Form 4)

      4 - Veradigm Inc. (0001124804) (Issuer)

      4/2/25 4:57:39 PM ET
      $MDRX
      EDP Services
      Technology

    $MDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Veradigm Inc.

      SC 13G - Veradigm Inc. (0001124804) (Subject)

      11/14/24 4:05:58 PM ET
      $MDRX
      EDP Services
      Technology
    • Amendment: SEC Form SC 13G/A filed by Veradigm Inc.

      SC 13G/A - Veradigm Inc. (0001124804) (Subject)

      11/14/24 1:11:13 PM ET
      $MDRX
      EDP Services
      Technology
    • Amendment: SEC Form SC 13G/A filed by Veradigm Inc.

      SC 13G/A - Veradigm Inc. (0001124804) (Subject)

      11/8/24 10:29:29 AM ET
      $MDRX
      EDP Services
      Technology

    $MDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Stonehill Capital Management Llc bought $66,001,500 worth of shares (10,222,875 units at $6.46) (SEC Form 4) (Amendment)

      4/A - Veradigm Inc. (0001124804) (Issuer)

      3/15/24 5:16:45 PM ET
      $MDRX
      EDP Services
      Technology
    • Stonehill Capital Management Llc bought $66,001,500 worth of shares (10,222,875 units at $6.46) (SEC Form 4)

      4 - Veradigm Inc. (0001124804) (Issuer)

      3/4/24 9:50:46 PM ET
      $MDRX
      EDP Services
      Technology

    $MDRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance
    • Syracuse Orthopedic Specialists Selects Veradigm to Achieve Exceptional Financial Health and Operational Efficiency

      Veradigm to provide a comprehensive solution set to optimize revenue cycle and coding processes Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that Syracuse Orthopedic Specialists has selected elements from the Veradigm solution suite, Veradigm Revenue Cycle Services and Coding Services designed to support growth, improve cash flow and reduce costs. Syracuse Orthopedic Specialists, located near Syracuse, NY, provides total orthopedic care to the surrounding regions, and is currently utilizing Veradigm Revenue Analytics, Veradigm Practice Management and Veradigm Payerpath. Veradigm Revenue Cycle Services provides a robust suite of solu

      4/2/25 8:01:00 AM ET
      $MDRX
      EDP Services
      Technology
    • Veradigm Announces Appointment of Two New Independent Directors and Transition of Board Leadership

      Appoints Jonathan Sacks and Bruce Felt to the Board Lou Silverman to Succeed Greg Garrison as Chairman Veradigm Inc. (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today its Board of Directors (the "Board") appointed two new independent directors, Jonathan Sacks and Bruce Felt, to the Board, effective March 19, 2025, and that Lou Silverman will succeed Greg Garrison as Chairman upon his retirement from the Board on that date. In addition, Mr. Felt will become the Chair of the Audit Committee of the Board upon Mr. Garrison's retirement. Further, independent director Vinit Asar has been named Chair of the Nominating and Go

      3/18/25 4:47:00 PM ET
      $CMBM
      $DOMO
      $EVH
      $MDRX
      Radio And Television Broadcasting And Communications Equipment
      Technology
      Computer Software: Prepackaged Software
      Other Consumer Services

    $MDRX
    Financials

    Live finance-specific insights

    See more
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance
    • Veradigm to Release Financial Update March 18th and Host Investor Call March 19th

      Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that management plans to provide a financial update after the close of regular stock market hours on March 18, 2025. Veradigm management plans to host an investor conference call and webcast to discuss the Company's update at 8:00 a.m. Eastern Time on March 19, 2025. Update Call Details Veradigm plans to distribute an announcement promptly after the close of regular stock market hours on Tuesday, March 18, 2025. The announcement will also be available at the Veradigm investor relations website. To listen to the conference call, participants may log onto the Veradigm investor relations we

      3/13/25 9:57:00 PM ET
      $MDRX
      EDP Services
      Technology
    • Veradigm Concludes Exploration of Strategic Alternatives and Announces Operational Review

      Engaged an Independent Strategic Advisor to Refine Go-Forward Plan Company to Provide a Financial and Business Update in March Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that the Veradigm Board of Directors (the "Board") completed its previously announced review of strategic alternatives to maximize stockholder value. Review of Strategic Alternatives Throughout the review process, the Board, in collaboration with its financial and legal advisors, evaluated potential strategic opportunities, including a possible sale of the Company. Following the May 2024 public announcement of the process, the Company entered into confidenti

      1/30/25 4:02:00 PM ET
      $MDRX
      EDP Services
      Technology

    $MDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Veradigm downgraded by Deutsche Bank with a new price target

      Deutsche Bank downgraded Veradigm from Buy to Hold and set a new price target of $10.00 from $15.00 previously

      3/19/24 7:50:39 AM ET
      $MDRX
      EDP Services
      Technology
    • Barclays initiated coverage on Veradigm with a new price target

      Barclays initiated coverage of Veradigm with a rating of Equal Weight and set a new price target of $11.00

      1/3/24 8:00:02 AM ET
      $MDRX
      EDP Services
      Technology
    • Veradigm downgraded by Argus

      Argus downgraded Veradigm from Buy to Hold

      7/6/23 9:00:49 AM ET
      $MDRX
      EDP Services
      Technology

    $MDRX
    SEC Filings

    See more
    • SEC Form 8-K filed by Veradigm Inc.

      8-K - Veradigm Inc. (0001124804) (Filer)

      4/22/25 4:23:28 PM ET
      $MDRX
      EDP Services
      Technology
    • SEC Form 8-K filed by Veradigm Inc.

      8-K - Veradigm Inc. (0001124804) (Filer)

      4/17/25 5:02:25 PM ET
      $MDRX
      EDP Services
      Technology
    • Amendment: SEC Form 8-K/A filed by Veradigm Inc.

      8-K/A - Veradigm Inc. (0001124804) (Filer)

      4/10/25 4:10:53 PM ET
      $MDRX
      EDP Services
      Technology

    $MDRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Veradigm Announces Appointment of Two New Independent Directors and Transition of Board Leadership

      Appoints Jonathan Sacks and Bruce Felt to the Board Lou Silverman to Succeed Greg Garrison as Chairman Veradigm Inc. (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today its Board of Directors (the "Board") appointed two new independent directors, Jonathan Sacks and Bruce Felt, to the Board, effective March 19, 2025, and that Lou Silverman will succeed Greg Garrison as Chairman upon his retirement from the Board on that date. In addition, Mr. Felt will become the Chair of the Audit Committee of the Board upon Mr. Garrison's retirement. Further, independent director Vinit Asar has been named Chair of the Nominating and Go

      3/18/25 4:47:00 PM ET
      $CMBM
      $DOMO
      $EVH
      $MDRX
      Radio And Television Broadcasting And Communications Equipment
      Technology
      Computer Software: Prepackaged Software
      Other Consumer Services
    • Veradigm Announces Board Expansion and Changes

      Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors Veradigm® (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today it has entered into a Cooperation Agreement (the "Agreement") with Kent Lake PR LLC ("Kent Lake"). The Agreement aligns with the Board's request for input from shareholders regarding board composition on January 30, 2025, and a desire to conduct an orderly refreshment of the Board following the conclusion of the exploration of strategic alternatives. As part of the Agreement, the Board has appointed two new independent directors, Vinit Asar and Louis Silve

      2/20/25 4:02:00 PM ET
      $MDRX
      $OCX
      $ZIMV
      EDP Services
      Technology
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Sprinklr Set to Join S&P SmallCap 600

      NEW YORK, Feb. 28, 2024 /PRNewswire/ -- Sprinklr Inc. (NYSE:CXM) will replace Veradigm Inc. (NASD:MDRX) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, March 4. Veradigm will be suspended from the Nasdaq Stock Market on February 29 due to non-compliance with NASDAQ listing rules and is no longer eligible for continued inclusion in the S&P SmallCap 600. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector March 4, 2024 S&P SmallCap 600 Addition Sprinklr CXM Information Technology March 4, 2024 S&P SmallCap 600 Deletion Veradigm MDRX Hea

      2/28/24 5:50:00 PM ET
      $CXM
      $MDRX
      $SPGI
      Computer Software: Prepackaged Software
      Technology
      EDP Services
      Finance: Consumer Services